PCV69 COST-EFFECTVENESS OF ENDOVASCULAR ANEURYSM REPAIR VERSUS OPEN SURGICAL REPAIR: NON-RUPTURED INFRARENAL ABDOMINAL AORTIC ANEURYSM IN AN ELECTIVE SETTING  by Hayes, P et al.
echocardiography (stress echo), exercise stress nuclear scintigra-
phy (stress nuclear), or exercise treadmill test (ETT) study. The
model was developed to evaluate the potential cost savings of
coronary CTA vs. cardiac catheterization in patients who have an
abnormal or non-diagnostic test result. RESULTS: A strategy
utilizing coronary CTA to evaluate patients with an abnormal or
non-diagnostic stress echo, stress nuclear, or ETT study was
cost-saving compared with a conventional strategy of cardiac
catheterization for these patients, up to a CAD prevalence rate
within the study population of 33–72%, depending on the
costs assumptions used in the model. CONCLUSIONS: An
evaluation strategy that uses coronary CTA for the primary
evaluation of patients with abnormal ETT, stress echo, or stress
nuclear test may reduce costs in a patient population with a low
to intermediate prevalence of CAD.
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OBJECTIVES: Acute heart failure (AHF) is life a threatening
disease which includes variable causes and complications. The
aim was to assess clinical characteristics, medication and costs
during hospitalization in patients with AHF. METHODS:
Patients hospitalized in a cardiological dpt. of the Faculty Hos-
pital Brno in January 2005–July2007 were classiﬁed according to
the Guidelines on the diagnosis and treatment of AHF by the
European Society of Cardiology and their medication was fol-
lowed at admission and during the stay. In-patient care costs
include ﬂat rate of admission, stay and medicinal procedures.
(1€ = 25 CZK) RESULTS: In total, 1213 patients (57.5% male,
mean age 72.5 years) with AHF were analyzed. The chronic
medication involved diuretics in 51%, less than half used anti-
platelet drugs, beta-blockers and ACE-I; statins (28.3%), nitrates
(23.6%), digoxin (21.8%). Positive inotropics were indicated in
acute state: norepinephrine (20.4%), dopamine (11.4%), dob-
utamine (10%), epinephrine (9.5%) and levosimendan (4.8%).
New-onset AHF (57%) was more common than decompensated
AHF and was concerned with higher costs. AHF with mild signs
and symptoms prevailed (49.3%), pulmonary oedema and car-
diogenic shock were both in 13%. Total direct in-hospital
expenses were €4.4 million; mean in-patient cost was €3621. The
most expensive were patients in cardiogenic shock with only 3
days of hospitalization (overall mean length-of-stay 8.2 days).
The predictors of high costs were antiarrhythmic interventions
(PM and ICD; 5.9% patients) making up to 21% of total
expenses and revascularizations (coronary angiography followed
by PCI in 31.5% patients) which made 41% of total expenses.
CONCLUSIONS: The treatment of heart failure patients uses
1–2% of health care budget in developed European countries of
which 2/3 are being spent on hospitalizations. AHF hospitaliza-
tion is more frequent as the population ages (62% patients were
more than 70 years old) and is associated with poor prognosis
(in-hospital mortality 14.5%).
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IMPACT OF DRUG ELUTING STENTS ON CLINICAL AND
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OBJECTIVES: To assess clinical and economic outcomes of PCI
following the commercial availability of drug-eluting stents
(DES). METHODS: We identiﬁed all patients undergoing PCI
from 2000–2002 (pre-DES era) and from 2004—April 31, 2006
(DES era) in a large PCI registry that includes demographic,
clinical, angiographic, procedural and outcome information.
Administrative data were used to estimate length of stay (LOS)
and procedural costs, as well as cardiac hospitalization costs
during year follow-up. We used logistic and Cox proportional
hazard models to estimate the adjusted risk of adverse events
within propensity score stratum and generalized linear modeling
to predict LOS, procedural and follow-up hospitalization costs
by treatment era. RESULTS: We compared 3422 patients from
the DES era (mean age 67, 69% male) and 4303 patients from
the pre-DES era (mean age 67, 70% male). 90% of pre-DES era
patients had bare-metal stents implanted; whereas 83% of DES
era patients had DES. Adverse event rates were similar between
time periods (adjusted odds ratio for in-hospital myocardial
infarction (MI) in DES era: 0.79; 95% CI 0.62, 1.00). During a
median 22 month follow-up, the adjusted incidence of death or
MI was similar between cohorts, but follow up procedures were
reduced in the DES era (hazard ratio for target lesion revascu-
larization in DES era vs. pre-DES era: 0.58; 95% CI 0.50, 0.68).
Models predict a mean LOS reduction of 0.40 days in the DES
era and procedural cost savings of $2053 (95% bootstrapped CI
of adjusted mean difference: -2937, -1197). Follow-up cardiac
hospitalization costs were similar. CONCLUSIONS: In a large
unselected PCI cohort, the introduction of DES was associated
with improved clinical outcomes during follow-up and reduced
in-hospital costs. These data suggest costly new technologies can
be introduced into a general practice setting while maintaining
and improving patient outcomes at an incremental cost savings.
PCV69
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OBJECTIVES: To determine the cost-effectiveness of endovascu-
lar aneurysm repair (EVAR) versus open surgical repair (OSR)
for non-ruptured, infrarenal abdominal aortic aneurysm (AAA)
in an elective setting. The analysis was conducted for the recent
appraisal of EVAR by the National Institute for Health and
Clinical Excellence in England and Wales. METHODS: A two-
stage cost-utility model was developed from an NHS perspective
to capture the lifetime costs and health outcomes of EVAR. The
model population represented a 70-year old, ﬁt for open surgery,
with an AAA at least 5.5 cm in diameter. A decision-tree model
captured the short-term costs and health outcomes of patients
during the ﬁrst 30-days post-repair, followed by a Markov
model, with monthly cycles during the ﬁrst 24 months and yearly
cycles thereafter, until death. Clinical endpoints included mortal-
ity and complications. Primary data were derived from the EVAR
I randomised controlled trial where reported. To reﬂect current
clinical practice other sources including retrospective patient
data were used. Costs were applied from trial data and national
reference sources. A discount rate of 3.5% was applied to costs
and health outcomes. Univariate and multivariate sensitivity
analyses were performed for all parameters. An incremental cost-
effectiveness ratio (ICER) reﬂecting incremental lifetime costs per
quality adjusted life year (QALY) gained was calculated for the
A402 Abstracts
base-case analysis. RESULTS: Base case analysis, resulted in an
ICER of £15,681 per QALY for EVAR versus OSR. The average
QALY gain at 30 years post surgery was 0.072 for EVAR com-
pared with OSR. Results were most sensitive to the relative risk
of short-term mortality, cost of the EVAR device and long-term
rate of secondary interventions in the EVAR group. CONCLU-
SIONS: The results suggest that EVAR is cost-effective for non-
ruptured AAA versus OSR with a probability of 66% and 60%
based on willingness-to-pay thresholds of £30,000 and £20,000,
respectively.
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OBJECTIVES: To determine if clopidogrel plus aspirin is cost-
effective compared to aspirin alone for patients following ACS,
from the Australian health care perspective. METHODS: A
Markov model was constructed by extrapolation of data from
the Australian Acute Coronary Syndromes Prospective Audit
(ACACIA) registry (n = 2553) in the ﬁrst model cycle, and
the Reduction in Atherothrombosis for Continued Health
(REACH) registry (n = 2567 Australian patients) in subsequent
cycles. Decision analysis was applied to compare clopidogrel
plus aspirin against aspirin alone. Efﬁcacy data were drawn
from the Clopidogrel in Unstable Angina to Prevent Recurrent
Events (CURE) trial. A utility study was conducted in 2007
with 86 participants using health states validated by clinical
experts. Drug and disease costs were obtained from literature
and health care reimbursement fees, and updated using Austra-
lian health price indices. An annual discount rate of 5% was
applied to all costs and effects beyond one year in accordance
with reimbursement guidelines. Twenty sensitivity analyses were
undertaken, varying the 95% conﬁdence intervals surrounding
efﬁcacy measures from CURE, uncertainty in cost and utility
inputs and variations to time horizons and discount rates.
RESULTS: The base-case incremental cost-effectiveness ratio
(ICER) with a ten-year time horizon was A$14,496/QALY and
remained below the unofﬁcial cost-effective threshold of
$A40,000/QALY throughout all sensitivity analyses. Treatment
remained cost-effective up to an inﬂated clopidogrel cost of
229%, and even when acute hospitalization costs were removed
(A$20,267/QALY). The ﬁve-year ICER was A$20,124/QALY.
Sensitivity analyses demonstrated that the ICER ranged from
A$6443/QALY when the risk of events observed in ACACIA
were applied to all years, up to A$36,974/QALY using the 95%
upper conﬁdence interval for efﬁcacy. CONCLUSIONS: Clopi-
dogrel with aspirin represents a highly cost-effective treatment
option for patients with ACS in Australia. This was conﬁrmed
by the Australian reimbursement authority’s recent recommen-
dation that treatment with clopidogrel plus aspirin be reim-
bursed for ACS patients.
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OBJECTIVES: Atrial ﬁbrillation is the most common arrhythmia
in the clinical practice. It is related with an important morbidity,
a decrease in patients’ quality of life and is a risk factor of
suffering a stroke. The Spanish estimated atrial ﬁbrillation preva-
lence is 2.52%, and is higher over 60 years. Radiofrequency
surgical ablation is a treatment alternative to restore sinus
rhythm in drug-refractory atrial ﬁbrillation patients. The main
objective of this study is to develop a ﬁve-year cost-utility analy-
sis including the different treatment alternatives in drug-
refractory concomitant atrial ﬁbrillation patients in the Spanish
setting. METHODS: A Markov model was developed to simu-
late the evolution of a 1000 cohort of over 40 years old patients
with paroxistical and persistent atrial ﬁbrillation that could be
treated with: non ablation, surgical ablation and catheter abla-
tion. The model included four heath states: sinus rhythm, atrial
ﬁbrillation, dependent stroke and death. The time horizon was
ﬁve years, with a cycle length of three months. The data of cost
and effects were obtained from the published literature and
experts opinion. Costs and effects were discounted at 3.5%. A
sensibility analysis was developed to determine the robustness of
the main variables of the model. RESULTS: Based on 1000
patients simulation with concomitant atrial ﬁbrillation, prelimi-
nary results show that the QALY gained were 3.79, 4.25, and
4.23, respectively for no ablation, surgical ablation and catheter
ablation. The costs per patient were respectively 8889, 11,157
and 11,865. The cost per QALY gained of the most effectiveness
option (surgical ablation) when compared with no ablation is
€4909. Surgical ablation is a dominant option vs. catheter abla-
tion. CONCLUSIONS: These preliminary results show that
surgical ablation is a cost-effective treatment option in drug
refractory concomitant atrial ﬁbrillation patients in the Spanish
setting, with less cost and a higher efﬁcacy than the catheter
ablation.
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COST/UTILITY ANALYSIS (CUA) OFVALSARTAN FORTHE
TREATMENT OF CONGESTIVE HEART FAILURE (CHF) IN
ITALY BASED ONTHEVAL-HEFTTRIAL
Pradelli L, Iannazzo S, Zaniolo O
AdRes Srl,Turin, Italy
OBJECTIVES: CUA of the use of valsartan when added to
standard treatment in CHF management in Italy. METHODS: A
probabilistic Markov model, made up of states corresponding to
NYHA classes II, III, IV, and death, was developed in WinBUGS
to apply ﬁndings from the Val-HeFT Trial to the Italian setting.
Simulation lasts 10 years, divided in 1-month cycles. Transition
probabilities represent individual mortality, derived from the
general population mortality by gender and age multiplied by a
NYHA state-speciﬁc HR, and probability of changing NYHA
class, derived from Val-HeFT. The model is informed with
NYHA state- and age-speciﬁc utilities and hospitalization prob-
abilities (adjusted for gender and ACEi-use). Costs are calculated
in the perspective of the Italian NHS and account for drugs and
CHF hospitalizations. The cohort was deﬁned to represent
Italian patients with mild-to-severe CHF and LFEV < 40% over
45 years (Val-HeFT inclusion criteria). Results were calculated
through 30,000 iterations of the patient-level simulation (each
individual is created by drawing from age, gender and ACE-I use
distributions of the cohort). Annual discount rate of 3.5% was
applied to costs and health outcomes. Uncertainty around model
parameters was handled by probabilistic sensitivity analysis
(PSA), performed by simultaneous drawing of each model
parameter from the original data source 95% CI, or from the +/-
10% range where original CI was unavailable. RESULTS: On
average, in the simulation timeframe patients live 4.4 years (3.2
QALYs), with a slight increase in the valsartan group, in which
costs are reduced by approximately €500/pt. In subgroup
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